Aberdeen Group
TARS icon

Aberdeen Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Aberdeen Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-51,678
Closed -$3.07M – 986
2025
Q3 		$3.07M Sell
51,678
-9,919
-16% -$488K ﹤0.01% 743
2025
Q2 		$2.5M Buy
61,597
+9,728
+19% +$438K ﹤0.01% 764
2025
Q1 		$2.66M Sell
51,869
-41,781
-45% -$2.07M 0.01% 738
2024
Q4 		$5.19M Sell
93,650
-8,905
-9% -$404K 0.01% 644
2024
Q3 		$3.37M Hold
102,555
– – 0.01% 713
2024
Q2 		$2.79M Buy
102,555
+30,523
+42% +$1.03M 0.01% 718
2024
Q1 		$2.62M Hold
72,032
– – 0.01% 749
2023
Q4 		$1.46M Buy
+72,032
New +$1.2M ﹤0.01% 803

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Aberdeen Group's TARS Position: Q4 2025 in Review

Aberdeen Group sold out of Tarsus Pharmaceuticals (TARS) in Q4 2025, closing a stake of 51,678 shares — an estimated $3.07M sold.

Aberdeen Group first reported a position in TARS in Q4 2023 and held it in 8 quarters. The position peaked at $5.19M in Q4 2024. 246 funds tracked by Wall St. Rank hold TARS as of Q4 2025.

  • Aberdeen Group reported no remaining Tarsus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Aberdeen Group sold 51,678 Tarsus Pharmaceuticals shares in Q4 2025, an estimated $3.07M.
  • Aberdeen Group first reported a position in Tarsus Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Aberdeen Group's Tarsus Pharmaceuticals position peaked at $5.19M in Q4 2024.
  • 246 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2025.

Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.